November 4, 2024 01:46 PM EST
Pharma

BioN­Tech eas­es 2024 rev­enue out­look de­spite hefty Covid vac­cine third-quar­ter sales

Ayisha Sharma

News Reporter

De­spite strong third-quar­ter rev­enues, BioN­Tech has soft­ened its 2024 sales guid­ance in light of changes to Covid-19 vac­cine up­take, pric­ing and sea­son­al vari­a­tions.

The com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times